Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Assets (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Current Assets for 9 consecutive years, with $577.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 2.38% to $577.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $577.6 million through Dec 2025, down 2.38% year-over-year, with the annual reading at $577.6 million for FY2025, 2.38% down from the prior year.
  • Current Assets hit $577.6 million in Q4 2025 for Protagonist Therapeutics, down from $586.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $627.6 million in Q1 2024 to a low of $235.7 million in Q1 2023.
  • Historically, Current Assets has averaged $418.2 million across 5 years, with a median of $348.5 million in 2022.
  • Biggest five-year swings in Current Assets: crashed 30.97% in 2023 and later surged 166.21% in 2024.
  • Year by year, Current Assets stood at $340.7 million in 2021, then fell by 28.66% to $243.1 million in 2022, then skyrocketed by 46.28% to $355.6 million in 2023, then surged by 66.39% to $591.6 million in 2024, then decreased by 2.38% to $577.6 million in 2025.
  • Business Quant data shows Current Assets for PTGX at $577.6 million in Q4 2025, $586.4 million in Q3 2025, and $602.5 million in Q2 2025.